Experts weigh role of florbetapir in Alzheimer's disease management

01/16/2013 |

Despite the debate surrounding the usefulness of Alzheimer's disease imaging agent florbetapir and problems with reimbursing the tests, the imaging agent is slowly becoming an important part of the Alzheimer's imaging field. A positive scan does not always mean that patients have the disease -- it just shows they are more at risk of developing it, while patients with a negative scan may still develop a different type of dementia. Some experts worry that without a definitive treatment for Alzheimer's, findings from the scan may not be very useful in terms of disease management. However, Dr. Mark Brody, president of Brain Matters Research in Delray Beach, Fla., said the test should be conducted as part of the overall diagnostic.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC